New Market Study Published: Resverlogix Corp. - Product Pipeline Review - 2012

New Pharmaceuticals market report from Global Markets Direct: "Resverlogix Corp. - Product Pipeline Review - 2012"

Logo

Boston, MA -- (SBWire) -- 12/18/2012 --Global Market Direct's pharmaceuticals report, "Resverlogix Corp. - Product Pipeline Review - 2012" provides data on the Resverlogix Corp.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Resverlogix Corp.'s corporate website, SEC filings, investor presentations and featured press releases, both from Resverlogix Corp. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Resverlogix Corp. - Brief Resverlogix Corp. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Resverlogix Corp. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Resverlogix Corp. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Resverlogix Corp.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

View Full Report Details and Table of Contents

Reasons to Get this Report

- Evaluate Resverlogix Corp.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Resverlogix Corp. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Resverlogix Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Resverlogix Corp..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Resverlogix Corp. and identify potential opportunities in those areas.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Synta Pharmaceuticals Corp. - Product Pipeline Review - 2012
- Anavex Life Sciences Corp. - Product Pipeline Review - 2012
- Raptor Pharmaceuticals Corp. - Product Pipeline Review - 2012
- Ophthotech Corp. - Product Pipeline Review - 2012
- Synageva BioPharma Corp. - Product Pipeline Review - 2012
- CHONG KUN DANG PHARMACEUTICAL CORP. - Product Pipeline Review - 2012
- Biotie Therapies Corp. - Product Pipeline Review - 2012
- Targa Therapeutics Corp. - Product Pipeline Review - 2012
- Angion Biomedica Corp. - Product Pipeline Review - 2012
- Tekmira Pharmaceuticals Corp. - Product Pipeline Review - 2012

Media Relations Contact

Bill Thompson
Director of Marketing
800-844-8156
http://www.fastmr.com

View this press release online at: http://rwire.com/186088